Skip to main content
Andrew Himelstein, MD, Oncology, Newark, DE

Andrew L Himelstein MD

Oncology•Newark, DE

Assistant Clinical Professor of Medicine, Thomas Jefferson University

Join to View Full Profile

  • 4701 Ogletown Stanton RdSte 3400Newark, DE 19713

  • Phone+1 302-366-1200

  • Fax+1 302-366-1700

Are you Dr. Himelstein?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
Claim this profileNot you? Find your profile

Summary

  • Dr. Andrew Himelstein, MD is an oncologist in Newark, Delaware. He is currently licensed to practice medicine in Delaware, New Jersey, and Pennsylvania. He is an Assistant Clinical Professor of Medicine at Thomas Jefferson University.

Education & Training

  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1988 - 1991
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1985 - 1988
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 1985

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1991 - 2026
  • DE State Medical License
    DE State Medical License 1991 - 2025
  • NJ State Medical License
    NJ State Medical License 1991 - 2005
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Hospice and Palliative Medicine
    American Board of Internal Medicine Hospice and Palliative Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • COMMENTARY: Start the Conversation with Your Doctor
    COMMENTARY: Start the Conversation with Your DoctorFebruary 17th, 2019
  • Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients with Bone Metastases
    Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients with Bone MetastasesJanuary 8th, 2017
  • Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
    Powerful Drug for Advanced Cancers May Need Less Frequent DosingJanuary 4th, 2017

Dr. Andrew Himelstein, Dr. Andrew Himelstein, MD, Dr. A Himelstein, Dr. Andrew L Himelstein